HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Gastrointestinal toxicity associated with weekly docetaxel treatment.

Abstract
Previous studies have demonstrated a marked reduction of haematological and non-haematological toxicity if weekly doses of docetaxel <40 mg/m2 were used. Reviewing the literature, neutropenic enterocolitis is uncommon but not unknown in patients treated with taxane-based chemotherapy. Although this complication occurs rarely, here we report on two patients, one with metastatic breast cancer and one with non-small-cell lung cancer, treated on a weekly schedule with single-agent docetaxel. Both patients developed excessive and fatal haemorrhragic gastroduodenitis and enterocolitis associated with grade 2 and 3 neutropenia. We would like to stress the importance of symptoms such as abdominal pain and tenderness, fever, diarrhoea and mucositis, with or without neutropenic fever, in patients treated with docetaxel-based chemotherapy. These symptoms should alert the physician and supportive care management should be started aggressively and immediately.
AuthorsH J Stemmler, S Kenngotte, H Diepolder, V Heinemann
JournalAnnals of oncology : official journal of the European Society for Medical Oncology (Ann Oncol) Vol. 13 Issue 6 Pg. 978-81 (Jun 2002) ISSN: 0923-7534 [Print] England
PMID12123345 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Taxoids
  • Docetaxel
  • Paclitaxel
Topics
  • Aged
  • Aged, 80 and over
  • Carcinoma, Non-Small-Cell Lung (drug therapy, pathology)
  • Digestive System (drug effects)
  • Docetaxel
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug-Related Side Effects and Adverse Reactions (diagnosis, etiology)
  • Enterocolitis (chemically induced)
  • Fatal Outcome
  • Female
  • Humans
  • Infusions, Intravenous
  • Lung Neoplasms (drug therapy, pathology)
  • Male
  • Multiple Organ Failure
  • Neoplasm Staging
  • Paclitaxel (administration & dosage, adverse effects, analogs & derivatives)
  • Risk Assessment
  • Taxoids

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: